Bank of America’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$72M Sell
1,309,788
-151,514
-10% -$6.2M ﹤0.01% 1421
2026
Q1
$48.5M Buy
1,461,302
+610,195
+72% +$18.2M ﹤0.01% 1614
2025
Q4
$25.4M Buy
851,107
+224,454
+36% +$7.33M ﹤0.01% 2090
2025
Q3
$22.6M Buy
626,653
+59,275
+10% +$1.95M ﹤0.01% 2507
2025
Q2
$20.4M Sell
567,378
-117,098
-17% -$4.36M ﹤0.01% 2536
2025
Q1
$27M Buy
684,476
+453,537
+196% +$15.3M ﹤0.01% 2144
2024
Q4
$6.95M Sell
230,939
-1,466,433
-86% -$42.1M ﹤0.01% 3278
2024
Q3
$39.7M Sell
1,697,372
-384,516
-18% -$8.4M ﹤0.01% 1770
2024
Q2
$37M Sell
2,081,888
-119,562
-5% -$1.91M ﹤0.01% 1696
2024
Q1
$33.5M Buy
2,201,450
+1,618,362
+278% +$25.8M ﹤0.01% 1802
2023
Q4
$9.96M Sell
583,088
-63,136
-10% -$734K ﹤0.01% 2897
2023
Q3
$5.4M Buy
646,224
+331,948
+106% +$4.63M ﹤0.01% 3337
2023
Q2
$7.81M Sell
314,276
-416,250
-57% -$10.8M ﹤0.01% 2961
2023
Q1
$11M Sell
730,526
-166,524
-19% -$2.53M ﹤0.01% 2730
2022
Q4
$10.6M Sell
897,050
-76,582
-8% -$556K ﹤0.01% 2637
2022
Q3
$5.76M Buy
973,632
+162,036
+20% +$1.06M ﹤0.01% 3193
2022
Q2
$3.45M Sell
811,596
-88,931
-10% -$555K ﹤0.01% 3778
2022
Q1
$8.56M Buy
900,527
+264,866
+42% +$3.07M ﹤0.01% 3018
2021
Q4
$12.1M Buy
635,661
+194,084
+44% +$5.04M ﹤0.01% 2735
2021
Q3
$14.7M Sell
441,577
-42,684
-9% -$1.32M ﹤0.01% 2461
2021
Q2
$18.8M Sell
484,261
-293,760
-38% -$11.5M ﹤0.01% 2195
2021
Q1
$37.5M Buy
778,021
+395,027
+103% +$19M ﹤0.01% 1513
2020
Q4
$19.9M Buy
382,994
+227,573
+146% +$7.69M ﹤0.01% 1898
2020
Q3
$4.16M Buy
155,421
+34,063
+28% +$784K ﹤0.01% 3084
2020
Q2
$2.36M Buy
121,358
+14,111
+13% +$227K ﹤0.01% 3484
2020
Q1
$1.05M Buy
107,247
+59,016
+122% +$745K ﹤0.01% 3977
2019
Q4
$535K Sell
48,231
-84,009
-64% -$639K ﹤0.01% 4972
2019
Q3
$743K Sell
132,240
-71,028
-35% -$495K ﹤0.01% 4783
2019
Q2
$1.76M Sell
203,268
-211,796
-51% -$1.6M ﹤0.01% 4130
2019
Q1
$3.34M Buy
415,064
+401,634
+2,991% +$2.17M ﹤0.01% 3549
2018
Q4
$55K Sell
13,430
-584,236
-98% -$2.9M ﹤0.01% 6176
2018
Q3
$3.35M Buy
597,666
+495,962
+488% +$5.67M ﹤0.01% 3542
2018
Q2
$1.34M Buy
101,704
+70,070
+222% +$964K ﹤0.01% 4282
2018
Q1
$449K Buy
31,634
+14,723
+87% +$188K ﹤0.01% 4895
2017
Q4
$138K Buy
16,911
+6,913
+69% +$60.4K ﹤0.01% 5591
2017
Q3
$119K Buy
9,998
+4,476
+81% +$51K ﹤0.01% 5612
2017
Q2
$55K Sell
5,522
-8,554
-61% -$95.7K ﹤0.01% 5832
2017
Q1
$164K Buy
14,076
+1,395
+11% +$10K ﹤0.01% 5404
2016
Q4
$59K Buy
12,681
+7,407
+140% +$43.4K ﹤0.01% 5857
2016
Q3
$41K Sell
5,274
-5,210
-50% -$33.5K ﹤0.01% 5808
2016
Q2
$63K Buy
10,484
+7,762
+285% +$63.1K ﹤0.01% 5734
2016
Q1
$23K Buy
2,722
+1,367
+101% +$12K ﹤0.01% 6087
2015
Q4
$16K Buy
1,355
+545
+67% +$6.88K ﹤0.01% 6515
2015
Q3
$8K Sell
810
-35,319
-98% -$526K ﹤0.01% 6647
2015
Q2
$599K Buy
36,129
+33,274
+1,165% +$527K ﹤0.01% 4555
2015
Q1
$44K Buy
2,855
+2,223
+352% +$33.7K ﹤0.01% 5719
2014
Q4
$10K Sell
632
-6,400
-91% -$83.3K ﹤0.01% 7064
2014
Q3
$75K Buy
+7,032
New +$65.2K ﹤0.01% 6228
2014
Q2
Sell
-27
Closed 8202
2014
Q1
$0 Sell
27
-506
-95% -$3K ﹤0.01% 8069
2013
Q4
$2K Sell
533
-7,394
-93% -$29.9K ﹤0.01% 7647
2013
Q3
$40K Sell
7,927
-16,008
-67% -$97.9K ﹤0.01% 6548
2013
Q2
$153K Buy
+23,935
New +$153K ﹤0.01% 5869

Other funds holding TGTX

Bank of America's TGTX Position: Q2 2026 in Review

Bank of America reduced its TG Therapeutics (TGTX) stake by 10% in Q2 2026, selling an estimated $6.2M and leaving 1,309,788 shares worth $72M. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Bank of America first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Bank of America held 1,309,788 shares of TG Therapeutics worth $72M as of Q2 2026.
  • Bank of America sold 151,514 TG Therapeutics shares in Q2 2026, an estimated $6.2M.
  • TG Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1421 holding.
  • Bank of America first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.